CELU

Celularity Inc. [CELU] Stock Forecast

Q: What is Celularity Inc. stock symbol ?

Celularity Inc. is a US stock, located in Florham park of Nj and trading under the symbol CELU

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CELU Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

EPS has increased from the previous year and become positive (Yearly statements)

Has a high level of debt. Debt-to-Equity ratio of 2.02 is considered high.

Earnings are expected to fall -100% next year

Profit margins (-12.27%) are lower than the previous year (0.79%)

CELU has less than 1 year of cash runway

Top 10 Correlated ETFs

CELU

Top 10 Correlated Stocks

CELU

In the News

CELU Financial details

Company Rating

Sell

Market Cap

89.53M

Income

-181.41M

Revenue

14.79M

Book val./share

1.61

Cash/share

0.01

Dividend

Dividend %

Employees

225

Optionable

Shortable

Yes

Earnings

12 Apr 2024

P/E

-0.26

Forward P/E

PEG

0.08

P/S

3.28

P/B

1.56

P/C

321

P/FCF

-0.71

Quick Ratio

0.08

Current Ratio

0.19

Debt / Equity

2.02

LT Debt / Equity

0.86

EPS (TTM)

-10.18

EPS next Y

EPS next Q

EPS this Y

-106.76%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

28.86%

EPS Q/Q

83.09%

SMA20

-24.56%

SMA50

2.61%

SMA100

108.17%

Inst Own

10.64%

Inst Trans

0.47%

ROA

-115%

ROE

-144%

ROC

-2.59%

Gross Margin

-141%

Oper. Margin

-1272%

Profit Margin

-1227%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.59-8.9

52W High

-59.88%

52W Low

+221%

RSI

30.22

Rel Volume

0.11

Avg Volume

268.06K

Volume

30.42K

Perf Week

-40.56%

Perf Month

-25.35%

Perf Quarter

62.12%

Perf Half Y

Beta

0.304

Volatility

0.65%, 0.79%

Prev Close

-3.02%

Price

3.21

Change

-13.01%

CELU Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	6.11	7.75	3.18	1.28
Net income per share	0	1.7	-113.06	-14.93	1.01
Operating cash flow per share	0	-0.32	-34.31	-16.42	-9.85
Free cash flow per share	0	-9.44	-49.42	-17.34	-10.23
Cash per share	0	0.26	29.49	5.55	1
Book value per share	0	76.08	-288.52	14.83	14.22
Tangible book value per share	0	-39.04	-423.55	-21.93	-2.99
Share holders equity per share	0	76.08	-288.52	14.83	14.22
Interest debt per share	0	-1.08	17.92	5.12	-7.09
Market cap	0	344.47M	202.6M	343.33M	180.48M
Enterprise value	125.29K	343.55M	178.93M	337.23M	232.1M
P/E ratio	0	58.6	-0.97	-3.43	12.72
Price to sales ratio	0	16.29	14.19	16.09	10.04
POCF ratio	0	-313.77	-3.21	-3.12	-1.31
PFCF ratio	0	-10.54	-2.23	-2.95	-1.26
P/B Ratio	0	1.31	-0.38	3.45	0.91
PTB ratio	0	1.31	-0.38	3.45	0.91
EV to sales	0	16.25	12.53	15.81	12.91
Enterprise value over EBITDA	0	-204.07	-2.73	-3.48	-1.64
EV to operating cash flow	0	-312.94	-2.83	-3.06	-1.68
EV to free cash flow	0	-10.51	-1.97	-2.9	-1.62
Earnings yield	0	0.02	-1.03	-0.29	0.08
Free cash flow yield	0	-0.09	-0.45	-0.34	-0.79
Debt to equity	0	0	-0.06	0.31	0.33
Debt to assets	0	0	0.07	0.08	0.16
Net debt to EBITDA	0	0.54	0.36	0.06	-0.37
Current ratio	0.16	4.4	2.7	1.42	0.54
Interest coverage	0	0.45	-33.17	-46.68	0.16
Income quality	0	-0.19	0.3	1.1	-9.72
Dividend Yield	0	0	0	0	0.22
Payout ratio	0	0	0	0	2.75
Sales general and administrative to revenue	0	0.03	2.14	3.33	3.66
Research and developement to revenue	0	2.18	3.69	4.14	4.36
Intangibles to total assets	0	1.37	0.58	0.6	0.6
Capex to operating cash flow	0	28.76	0.44	0.06	0.04
Capex to revenue	0	-1.49	-1.95	-0.29	-0.29
Capex to depreciation	0	-5.1	-3.41	-0.7	-0.55
Stock based compensation to revenue	0	0.17	0.31	1.88	0.88
Graham number	0	53.92	856.72	70.57	18.01
ROIC	0	-0.01	0.16	-0.92	-0.09
Return on tangible assets	0	-0.05	-1.14	-0.6	0.09
Graham Net	0	-6.75	-489.34	-40.08	-12.89
Working capital	-125.85K	780.06K	45.48M	11.02M	-28.59M
Tangible asset value	23.9K	-135.14M	-780.08M	-147.07M	-41.79M
Net current asset value	-125.85K	-27.2M	-890.25M	-277.47M	-168.66M
Invested capital	0	0	-0.06	0.31	0.33
Average receivables	0	1.54M	4.81M	5.89M	6.1M
Average payables	0	1.85M	4.54M	7.35M	7.56M
Average inventory	0	1.62M	3.54M	6.7M	7.43M
Days sales outstanding	0	53.13	167.44	89.53	141.45
Days payables outstanding	0	213.03	398.89	352.3	107.84
Days of inventory on hand	0	186.54	284.92	361.07	98.52
Receivables turnover	0	6.87	2.18	4.08	2.58
Payables turnover	0	1.71	0.92	1.04	3.38
Inventory turnover	0	1.96	1.28	1.01	3.7
ROE	0	0.02	0.39	-1.01	0.07
Capex per share	0	-9.12	-15.11	-0.93	-0.37

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.03	0.28	0.25	0.17	0.2
Net income per share	0.03	1.64	-4.12	-2.72	-4.98
Operating cash flow per share	-0.25	-1.99	-0.97	-0.62	-0.44
Free cash flow per share	-0.26	-2.04	-1.17	-0.63	-0.45
Cash per share	0.28	0.94	0.55	0.17	0.01
Book value per share	1.09	13.36	10.02	6.71	1.61
Tangible book value per share	-0.54	-2.81	-3.53	0.93	0.6
Share holders equity per share	1.09	13.36	10.02	6.71	1.61
Interest debt per share	0.38	0.39	4.12	3.57	3.29
Market cap	3.48B	192.11M	96.33M	94.11M	41.81M
Enterprise value	3.5B	243.73M	151.53M	152.97M	102.61M
P/E ratio	181.16	1.97	-0.38	-0.49	-0.11
Price to sales ratio	841.02	46.53	24.48	32.03	11.04
POCF ratio	-92.2	-6.49	-6.42	-8.53	-5.02
PFCF ratio	-88.53	-6.33	-5.29	-8.51	-4.89
P/B Ratio	21.17	0.97	0.62	0.79	1.38
PTB ratio	21.17	0.97	0.62	0.79	1.38
EV to sales	846.95	59.03	38.51	52.07	27.1
Enterprise value over EBITDA	-98.93	-7.42	-2.89	-6.95	-7.87
EV to operating cash flow	-92.85	-8.24	-10.11	-13.87	-12.33
EV to free cash flow	-89.15	-8.03	-8.32	-13.83	-12
Earnings yield	0	0.13	-0.66	-0.51	-2.25
Free cash flow yield	-0.01	-0.16	-0.19	-0.12	-0.2
Debt to equity	0.41	0.33	0.41	0.52	2.02
Debt to assets	0.15	0.16	0.18	0.25	0.39
Net debt to EBITDA	-0.69	-1.57	-1.05	-2.68	-4.66
Current ratio	0.91	0.54	0.38	0.28	0.19
Interest coverage	0.54	-0.29	-230.58	-38.47	-102.22
Income quality	-7.86	-1.21	0.23	0.23	0.09
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	4.58	0	0	0
Research and developement to revenue	4.92	2.66	4.31	2.93	1.37
Intangibles to total assets	0.56	0.6	0.58	0.41	0.12
Capex to operating cash flow	0.04	0.03	0.21	0	0.03
Capex to revenue	-0.38	-0.19	-0.82	-0.01	-0.06
Capex to depreciation	-0.65	-0.32	-1.36	-0.01	-0.1
Stock based compensation to revenue	1.09	1.06	1.01	1.31	0.95
Graham number	0.88	22.2	30.47	20.25	13.42
ROIC	-0.02	0.06	-0.26	-0.19	-0.86
Return on tangible assets	0.02	0.15	-0.42	-0.33	-0.68
Graham Net	-1.47	-12.11	-12.33	-6.7	-6.35
Working capital	-6.12M	-28.59M	-41.45M	-46.94M	-68.13M
Tangible asset value	-80.62M	-41.79M	-54.89M	16.33M	11.35M
Net current asset value	-209.78M	-168.66M	-181.78M	-109.88M	-110.45M
Invested capital	0.41	0.33	0.41	0.52	2.02
Average receivables	7.5M	7.67M	6.07M	5.02M	5.54M
Average payables	9.72M	7.51M	7.28M	10.6M	12.69M
Average inventory	14.95M	5.27M	5.4M	5.61M	5.34M
Days sales outstanding	182.22	151.84	118.13	149.61	147.05
Days payables outstanding	114.99	99.66	30.69	1.07K	323.1
Days of inventory on hand	65.37	91.05	19.22	494.18	123.28
Receivables turnover	0.49	0.59	0.76	0.6	0.61
Payables turnover	0.78	0.9	2.93	0.08	0.28
Inventory turnover	1.38	0.99	4.68	0.18	0.73
ROE	0.03	0.12	-0.41	-0.4	-3.1
Capex per share	-0.01	-0.05	-0.21	0	-0.01

CELU Frequently Asked Questions

What is Celularity Inc. stock symbol ?

Celularity Inc. is a US stock , located in Florham park of Nj and trading under the symbol CELU

What is Celularity Inc. stock quote today ?

Celularity Inc. stock price is $3.21 today.

Is Celularity Inc. stock public?

Yes, Celularity Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 268.06K
Market Capitalization 89.53M
Employee 225
CEO Dr. Robert Joseph Hariri M.D., Ph.D.
Headquarters Florham Park,NJ,US
IPO Date 2019-08-08
Website https://www.celularity.com

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.